Overview

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who did not respond to previous treatment.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Interferon-alpha
Peginterferon alfa-2b
Ribavirin
Criteria
Inclusion Criteria:

- Genotype 2, chronic hepatitis C

- Non-responders (patient who did not respond to previous treatment)

- Able and willing to follow contraception requirements

Exclusion Criteria:

- Cirrhosis of the liver or hepatic failure

- Hepatitis B surface antigen-positive or HIV antibodies-positive

- History of, or concurrent hepatocellular carcinoma

- History of, or concurrent depression, schizophrenia,; or suicide attempt in the past

- Pregnant, lactating, or suspected pregnant patients, or male patients whose female
partner is pregnant